TY - JOUR
T1 - Association between different stages of cardiovascular-kidney-metabolic syndrome and the risk of all-cause mortality
AU - Li, Na
AU - Li, Yaqi
AU - Cui, Liufu
AU - Shu, Rong
AU - Song, Haicheng
AU - Wang, Jierui
AU - Chen, Shuohua
AU - Liu, Bailu
AU - Shi, Huijing
AU - Gao, Huanqing
AU - Huang, Tao
AU - Gao, Xiang
AU - Geng, Tingting
AU - Wu, Shouling
N1 - Publisher Copyright:
© 2024 Elsevier B.V.
PY - 2024/10
Y1 - 2024/10
N2 - Background and aims: Poor cardiovascular-kidney-metabolic (CKM) health is a major determinant of all-cause mortality, which poses a significant burden on global public health systems and socio-economics. However, the association between different stages of CKM syndrome and the risk of all-cause mortality remains unclear. This study aimed to evaluate the association between different stages of CKM syndrome and risk of all-cause mortality. Methods: A total of 97,777 adults from the Kailuan Study were included. Cox proportional hazards regression models were applied to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) of all-cause mortality according to different stages of CKM syndrome. Results: Over a median follow-up of 15.0 (14.7–15.2) years, we identified 14,805 all-cause mortality cases. The stage of CKM syndrome was positively associated with the risk of all-cause mortality (p-trend <0.001). Compared with Stage 0, the multivariable-adjusted HRs (95 % CIs) of all-cause mortality were 1.24 (1.06–1.45) for Stage 1, 1.72 (1.48–2.00) for Stage 2, 2.58 (2.22–3.01) for Stage 3 and 3.73 (3.19–4.37) for Stage 4. Moreover, the observed associations were more pronounced in younger adults (aged <60 years) compared with older adults (p for interaction <0.001). Conclusions: Our data showed that a higher stage of CKM syndrome was associated with a higher risk of all-cause mortality, with a particularly pronounced association observed in younger adults. The study emphasized the need for targeted public health strategies and clinical management tailored to the stages of CKM syndrome, aiming to alleviate its burden on individuals and healthcare systems.
AB - Background and aims: Poor cardiovascular-kidney-metabolic (CKM) health is a major determinant of all-cause mortality, which poses a significant burden on global public health systems and socio-economics. However, the association between different stages of CKM syndrome and the risk of all-cause mortality remains unclear. This study aimed to evaluate the association between different stages of CKM syndrome and risk of all-cause mortality. Methods: A total of 97,777 adults from the Kailuan Study were included. Cox proportional hazards regression models were applied to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) of all-cause mortality according to different stages of CKM syndrome. Results: Over a median follow-up of 15.0 (14.7–15.2) years, we identified 14,805 all-cause mortality cases. The stage of CKM syndrome was positively associated with the risk of all-cause mortality (p-trend <0.001). Compared with Stage 0, the multivariable-adjusted HRs (95 % CIs) of all-cause mortality were 1.24 (1.06–1.45) for Stage 1, 1.72 (1.48–2.00) for Stage 2, 2.58 (2.22–3.01) for Stage 3 and 3.73 (3.19–4.37) for Stage 4. Moreover, the observed associations were more pronounced in younger adults (aged <60 years) compared with older adults (p for interaction <0.001). Conclusions: Our data showed that a higher stage of CKM syndrome was associated with a higher risk of all-cause mortality, with a particularly pronounced association observed in younger adults. The study emphasized the need for targeted public health strategies and clinical management tailored to the stages of CKM syndrome, aiming to alleviate its burden on individuals and healthcare systems.
UR - https://www.scopus.com/pages/publications/85203412135
UR - https://www.scopus.com/inward/citedby.url?scp=85203412135&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2024.118585
DO - 10.1016/j.atherosclerosis.2024.118585
M3 - Article
C2 - 39255681
AN - SCOPUS:85203412135
SN - 0021-9150
VL - 397
JO - Atherosclerosis
JF - Atherosclerosis
M1 - 118585
ER -